Silas Inman

The FDA has approved MM-398, branded as Onivyde (irinotecan liposome injection) in combination with 5-fluorouracil (5-FU) chemotherapy and leucovorin for patients with metastatic pancreatic cancer. The treatment follows prior administration of a gemcitabine-based regimen.

The American Cancer Society (ACS) has revised its breast cancer screening guidelines, recommending that women at an average risk of breast cancer receive a mammography annually starting at age 45-5 years later than previous recommendations formulated in 2003.

Optune (formally the NovoTTF-100A System) in combination with adjuvant temozolomide, has been approved by the FDA to treat patients newly diagnosed with glioblastoma multiforme (GBM) following surgery, chemotherapy, and radiation therapy.

The FDA has approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a treatment for patients with BRAF V600 wild-type unresectable or metastatic melanoma

The US Preventive Services Task Force issued a draft guideline today recommending the use of low-dose aspirin for certain individuals for the prevention of CRC and cardiovascular disease.

Patients with Hodgkin lymphoma at risk of relapse or progression have a new treatment option following the FDA's expansion of the approved use of brentuximab vedotin (Adcetris).

Results from the phase III TELESTAR trial showed that oral telotristat etiprate proved much better than placebo in reducing carcinoid syndrome–related diarrhea.

Treatment strategies for patients with myelodysplastic syndromes are built upon a foundation of supportive care, which consists of transfusions, iron chelation, and growth factor therapy.

The PD-L1 inhibitor MPDL3280A demonstrated a 19% objective response rate (ORR) with 75% of responses ongoing in pretreated patients with metastatic triple-negative breast cancer (TNBC), according to findings from an ongoing phase I study presented at the 2015 AACR Annual Meeting.

The FDA has granted an accelerated approval to the anti-CD19 immunotherapy blinatumomab as a treatment for patients with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia.

The FDA has approved ruxolitinib (Jakafi) as a treatment for patients with polycythemia vera (PV) who are resistant or intolerant to hydroxyurea, marking the first treatment specifically approved for patients with PV.

The FDA has expanded the approval for the androgen receptor inhibitor enzalutamide (Xtandi) to include the treatment of men with chemotherapy-naive mCRPC.

The FDA has approved eltrombopag (Promacta) as a treatment for patients with severe aplastic anemia (SAA) following an insufficient response to immunosuppressive therapy, based on data from an open-label, single-arm phase II trial.

The FDA has approved bevacizumab (Avastin) in combination with paclitaxel and cisplatin or paclitaxel and topotecan as a treatment for patients with persistent, recurrent, or metastatic cervical cancer

The FDA has approved Cologuard as the first noninvasive stool-based DNA test for the detection of colorectal cancer (CRC) in asymptomatic individuals at average risk, based on clinical trial results demonstrating superiority to the fecal immunochemical test (FIT).

Women harboring a loss-of-function mutation in the PALB2 gene demonstrated an increased risk of developing breast cancer that was similar to the predisposition seen with mutations in the infamous BRCA gene, according to a study published in The New England Journal of Medicine (NEJM).

The FDA has issued a drug safety communication regarding the risk of intoxication with the intravenous ethanol-containing chemotherapy docetaxel. The drug is marketed as generic docetaxel and under the brand names Taxotere, Docefrez, and Docetaxel Injection.

The ASCO clinical practice guideline now recommends treatment with adjuvant tamoxifen for 10 years in women with stage I-III hormone receptor (HR)-positive breast cancer.

A home administration route for the subcutaneous injection omacetaxine mepesuccinate (Synribo) was approved by the FDA for use in patients with chronic or accelerated phase chronic myeloid leukemia (CML) who are resistant or intolerant to treatment with tyrosine kinase inhibitors.

The FDA has granted an accelerated approval to the next-generation ALK inhibitor ceritinib as a treatment for patients with ALK-positive metastatic non-small cell lung cancer following progression on crizotinib.

The FDA has granted the first-ever approval for a diagnostic test alternative to Pap smear, the cobas HPV Test, despite objections from a number of organizations and healthcare providers.

The FDA has approved ramucirumab (Cyramza) as a single-agent treatment for patients with unresectable or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma following fluoropyrimidine- or platinum-containing therapy.

The FDA has approved ofatumumab (Arzerra) plus chlorambucil for previously untreated patients with chronic lymphocytic leukemia (CLL) who are considered inappropriate for treatment with the chemotherapy fludarabine.

Palbociclib, an inhibitor of cyclin-dependent kinases (CDK) 4 and 6, more than doubled progression-free survival (PFS) when used in combination with letrozole for patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer